腹膜透析相关腹膜纤维化的防治策略研究进展  

Research progress on prevention and treatment strategies for peritoneal fibrosis related to peritoneal dialysis

作　　者：刘萌萌 张秋花 LIU Mengmeng;ZHANG Qiuhua(Department of Nephrology,Central Hospital Affiliated to Jiangnan University(Wuxi No.2 People's Hospital),Wuxi 214000,China)

机构地区：[1]江南大学附属中心医院、无锡市第二人民医院肾内科,江苏无锡214000

出　　处：《山东医药》2025年第4期128-131,135,共5页Shandong Medical Journal

基　　金：江苏省无锡市卫健委中青年拔尖人才资助计划项目(HB2023029)。

摘　　要：腹膜透析是治疗终末期肾脏病患者有效的肾脏替代疗法,但腹膜长期暴露于高糖透析液中易引起腹膜纤维化,继而改变腹膜结构和功能,导致腹膜透析治疗失败。目前临床上防治腹膜纤维化的方法有限,主要包括通过药物防治及通过改善透析液的生物相容性防治等,但这些方法仍需进一步改进和创新。深入研究腹膜纤维化的防治策略,对于早期预防其发生、延长腹膜透析的治疗时间以及提高腹膜透析的临床治疗水平具有重要意义。Peritoneal dialysis is an effective renal replacement therapy for patients with end-stage renal disease.How-ever,long-term exposure of the peritoneum to high-glucose dialysis solutions can easily induce peritoneal fibrosis,which subsequently alters the structure and function of the peritoneum,ultimately leading to the failure of peritoneal dialysis ther-apy.Currently,clinical methods for preventing and treating peritoneal fibrosis are limited,primarily including pharmaco-logical interventions,and interventions of improving the biocompatibility of dialysis solutions,and others.Nevertheless,these approaches necessitate ongoing refinement and novel advancements.In-depth research into prevention and treatment strategies for peritoneal fibrosis holds significant importance for early prevention of its occurrence,extending the duration of peritoneal dialysis therapy,and enhancing the clinical efficacy of peritoneal dialysis.

关 键 词：腹膜透析 腹膜纤维化 钠-葡萄糖协同转运蛋白2抑制剂 生物相容性 

分 类 号：R692.5[医药卫生—泌尿科学]